Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (" NervGen " or the " Company "), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, is pleased to announce that it has established an at-the-market equity program (the " ATM Program ") that allows the Company to issue and sell common shares in the capital of the Company... Read More

Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury (SCI) is approaching completion NVG-300 preclinical test-of-concept studies in ischemic stroke, amyotrophic lateral sclerosis (ALS) and SCI underway Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company... Read More

Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announced today that Mr. Mike Kelly, President & CEO, will be participating in a fireside chat at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024, at 10:20 a.m. EST. Members of management will be... Read More

Target enrollment in the chronic cohort close to completion Vancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that target enrollment of the chronic cohort in its Phase 1b/2a proof-of-concept, double-blind, randomized... Read More

Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., NervGen's Chief Medical Officer, will give an oral presentation at the Unite 2 Fight Paralysis (U2FP) 19th Annual Science & Advocacy... Read More

Vancouver, British Columbia--(Newsfile Corp. - September 16, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., NervGen's Chief Medical Officer, will present at the 63 rd International Spinal Cord Society (ISCoS) Annual Scientific Meeting , taking... Read More

Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, on Tuesday, September 10, 2024, at 9:30 a.m. EDT.... Read More

Targeting to complete enrollment in the Phase 1b/2a chronic cohort in Q3 2024 Protocol being amended to enhance enrollment and lessen burden on participants in the subacute cohort NVG-300 advanced into preclinical proof-of-concept studies in ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI) Vancouver, British Columbia--(Newsfile Corp. - August 22, 2024) - NervGen Pharma Corp. (TSXV: NGEN)... Read More

Vancouver, British Columbia--(Newsfile Corp. - August 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the Canaccord Genuity 44 th Annual Growth Conference, on August 13, 2024, at 10:00 a.m. EDT and members of... Read More

Vancouver, British Columbia--(Newsfile Corp. - August 2, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 30,000 incentive stock options to employees of the company and 15,000 incentive stock options to existing consultants providing investor relations... Read More

Seasoned pharmaceutical executive with extensive experience in high-growth life sciences companies joins NervGen Leadership appointment supports the company's mission to advance NVG-291 after the completion of the ongoing Phase 1b/2a study Vancouver, British Columbia--(Newsfile Corp. - July 22, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative... Read More

New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced its plans for the development of a new drug... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting a corporate update at the 2 nd Annual Spinal Cord Injury Investor Symposium ("2 nd SCIIS"), presented by Lineage Cell... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 950,000 incentive stock options to directors and consultants of the company exercisable at a price of $1.79 per share (the "Options"). 400,000 of the... Read More

All resolutions submitted for approval were passed by shareholders Glenn Ives appointed as Chair of the Board John Ruffolo appointed as Chair of the Audit Committee Vancouver, British Columbia--(Newsfile Corp. - June 5, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announces the results of... Read More

Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical Officer, will be presenting two posters at the upcoming American Spinal Injury Association (ASIA) 51 st Annual Scientific Meeting... Read More

Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024 Subacute cohort protocol being amended to enhance feasibility and lessen burden on participants CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Vancouver, British Columbia--(Newsfile Corp. - May 16, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a... Read More

Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen's Board of Directors Annual General Meeting of Shareholders to be held on June 4, 2024 Vancouver, British Columbia--(Newsfile Corp. - May 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Russo Partners LLC ("Russo Partners"), a New York based full-service strategic communications firm to provide media and public... Read More

Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injury Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX:... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 28, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (" NervGen " or the " Company ") is pleased to announce the closing of its previously announced public offering (the " Offering ") including the full exercise of the underwriters' over-allotment option for aggregate gross proceeds to the Company of C$23,011,788. The Offering was made pursuant to an underwriting agreement... Read More

VANCOUVER, BC , March 21, 2024 /CNW/ - NervGen Pharma Corp. (" NervGen " or the " Company ") (TSXV: NGEN) is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Stifel Canada, Canaccord Genuity and PI Financial (collectively, the " Underwriters "), who have agreed to purchase, on a "bought deal" basis 8,515,000 units (the " Units ") of the Company at a price of $2.35 per Unit,... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 21, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has been recognized by the TSX Venture Exchange as a 2023 Top 50 Company. The 2024 TSX Venture 50™ showcases the strongest performances on the TSX Venture Exchange over the last year.... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that it has granted incentive stock options to the Company's employees, including 505,200 to the Company's Officers exercisable at a price of $3.48 per share for a period... Read More

On track to complete enrollment of the chronic cohort in Q2 2024 Data readout from chronic cohort expected in Q3 2024 Planning underway to make NVG-291 available to placebo-treated subjects following cohort completion Vancouver, British Columbia--(Newsfile Corp. - February 15, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the... Read More

Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic cohort expected in mid-2024 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injury Seasoned financial industry executive, John Ruffolo, appointed to Board Vancouver, British Columbia--(Newsfile Corp. - November 9, 2023) - NervGen Pharma Corp. (TSXV: NGEN)... Read More

Dr. Silver's life work, culminating in NervGen's NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal cord injury. Vancouver, British Columbia--(Newsfile Corp. - November 8, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that renowned... Read More

Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs Enrollment Progressing in NVG-291 Phase 1b/2a Clinical Trial, with Initial Cohort Data Expected in Mid-2024 Vancouver, British Columbia--(Newsfile Corp. - October 23, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the treatment... Read More

Extensive experience in private equity, venture capital and advising high growth, innovative companies Brings personal experience and knowledge of spinal cord injury to NervGen's board Important board addition joins as Company advances clinical milestone with Phase 1b/2a study of NVG-291 underway. Vancouver, British Columbia--(Newsfile Corp. - October 17, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical... Read More

Chronic spinal cord injury cohort results expected in mid-2024 Subacute spinal cord injury cohort results expected in late 2024/early 2025 Vancouver, British Columbia--(Newsfile Corp. - September 25, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the first subject has been... Read More

Vancouver, British Columbia--(Newsfile Corp. - September 11, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that its Chief Medical Officer, Dr. Daniel Mikol, will present at the 2023 International Spinal Research Trust Network Meeting being held... Read More

Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that President & CEO, Mike Kelly, will present at the H.C. Wainwright 25 th Annual Global Investment Conference on September 13, 2023 at 4:00pm Eastern Daylight Time (EDT)... Read More

Vancouver, British Columbia--(Newsfile Corp. - August 22, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that members of its management team will present at the KOL Discussion on Spinal Cord Injury hosted by PropThink Digital Conferences. President & CEO, Mike Kelly, and Chief... Read More

Landmark Phase 1a/2b clinical trial of NVG-291 proceeds with recruitment of individuals with spinal cord injury; results expected in mid-2024 Seasoned life sciences executive, Mike Kelly, appointed President & CEO Awarded grant of up to US$3.18 million from Wings for Life to support clinical trial Vancouver, British Columbia--(Newsfile Corp. - August 9, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or... Read More

Recruitment of individuals with spinal cord injury (SCI) initiated at Shirley Ryan AbilityLab in Chicago Chronic SCI cohort results expected in mid-2024 and subacute SCI cohort results in late 2024/early 2025 Vancouver, British Columbia--(Newsfile Corp. - August 8, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that it has been awarded a grant of up to US$3.18 million from Wings for Life, a not-for-profit spinal cord injury research foundation, under the... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 20, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that members of its management will be presenting at two upcoming investor conferences: Mike Kelly, President & CEO, will present at the Life... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 2, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced a two-year extension of the expiry date of certain stock options (the " Options ") granted to a consultant of the Company on April 23, 2021 and July 16,... Read More

Vancouver, British Columbia--(Newsfile Corp. - May 23, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 400,000 incentive stock options to directors of the Company, exercisable at a price of $1.61 per share for a period of five... Read More

All resolutions submitted for approval were passed by shareholders Vancouver, British Columbia--(Newsfile Corp. - May 18, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announces the results of its Annual General Meeting of Shareholders ("AGM") held on May 17, 2023. "We appreciate the support... Read More

Phase 1 clinical trial dosing completed Phase 1b/2a clinical trial of NVG-291 in individuals with chronic and subacute spinal cord injuries expected to commence in Q3 2023 Cash and investments of $18.0 million as of March 31, 2023 Vancouver, British Columbia--(Newsfile Corp. - May 15, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to... Read More

Phase 1b/2a trial expected to commence in Q3 2023 First readout anticipated in 2024 Vancouver, British Columbia--(Newsfile Corp. - April 13, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be giving an oral presentation at the upcoming American Spinal Injury... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 10, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of Mr. Michael Kelly to the position of President & CEO effective April 10, 2023. Mr. Kelly has also been appointed as a member of... Read More

Equity proceeds of CA$22M+ raised during 2022 fiscal year Phase 1 clinical trial dosing of proprietary compound, NVG-291, is complete and data analysis is ongoing Phase 1b/2a clinical trial of NVG-291 to include individuals with chronic and subacute spinal cord injuries Vancouver, British Columbia--(Newsfile Corp. - March 30, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical... Read More

Vancouver, Canada--(Newsfile Corp. - February 23, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 285,000 incentive stock options to directors of the Company and 10,000 incentive stock options to existing consultants providing... Read More

Completed NVG-291 dosing of subjects in Phase 1 clinical trial Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury planned to start in Q3 2023 NVG-291 has been demonstrated in preclinical studies to promote repair mechanisms in the nervous system, including axonal regeneration, remyelination and plasticity Vancouver, British Columbia--(Newsfile Corp. - February 14, 2023) - NervGen Pharma Corp. (TSXV:... Read More

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the US Patent and Trade Office (USPTO) has issued US Patent No. 11,497,812 B2 Compositions and Methods for Inhibiting the Activity of LAR Family Phosphatases to Case Western Reserve University. NervGen has an... Read More

Dosing completed in third dose cohort of multiple ascending dose (MAD) portion of Phase 1 clinical trial in postmenopausal females U.S. Food and Drug Administration (FDA) amendment of partial clinical hold allows for bridging cohorts of males and premenopausal females in the Phase 1 trial to commence Glenn Ives appointed as Lead Independent Director Vancouver, British Columbia--(Newsfile Corp. - November 14, 2022) - NervGen... Read More

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Cloutier Consulting, a Texas based public relations specialty agency, to provide media relations and related services for the Company. Cloutier Consulting was engaged for an initial term of one... Read More

Dose(s) to be tested in bridging cohorts of males and premenopausal females resulted in significant functional improvements in animal models of nervous system damage NervGen has completed enrollment of third and final multiple ascending dose cohort of postmenopausal women NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative... Read More

AMERICAN NEUROLOGICAL ASSOCIATION ANNUAL MEETING EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting posters at two upcoming scientific meetings - the 147 th American Neurological Association... Read More

The $1.5 million award is to evaluate the ability of NervGen's NVG-291-R to accelerate and enhance restoration of function following peripheral nerve injury (PNI) The research is to support a potential game changing therapeutic approach to restore function for US military service members and the estimated 20+ million Americans suffering from PNI There are currently no effective regenerative pharmaceuticals to enhance... Read More

All resolutions submitted for approval were passed by shareholders NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announces the results of its Annual General Meeting of Shareholders ("AGM") held on September 28, 2022. "We appreciate the support from our shareholders demonstrated at this AGM,"... Read More

Bill Radvak, Co-founder and Executive Chairman of the Board, appointed interim Chief Executive Officer Dr. Adam Rogers, member of the Board of Directors, appointed interim President Paul Brennan to step down as President & Chief Executive Officer and member of the Board of Directors; will serve as a strategic advisor for a transition period NervGen Pharma Corp. (OTCQX: NGENF) (TSXV: NGEN), a clinical stage biotech company... Read More

Expands research capabilities aiming to build pipeline of proprietary compounds for nervous system repair Dr. Lukashev brings over 20 years' experience including work at Biogen and the ALS Therapy Development Institute NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, is... Read More

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will present a poster at the upcoming Military Health System Research Symposium (MHSRS) on September 12-15, 2022 and will also present an oral presentation at the 61 st International Spinal Cord Society (ISCoS) Annual... Read More

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, today reported its financial results for the second quarter ended June 30, 2022 and provided an operational update. "We are also extremely pleased to have recently raised more than $22 million in equity funding to prepare... Read More

NervGen Pharma Corp. , (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will present the study design for its upcoming Phase 1b/2a Alzheimer's disease clinical trial at the 2022 Alzheimer's Association International Conference (AAIC) on August 3, 2022. NervGen's Chief Medical Officer, Dr. Daniel Mikol, will present a... Read More

NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) , is pleased to announce the University of Cincinnati and Case Western Reserve University (CWRU) have published a pioneering preclinical study in the peer-reviewed scientific journal Cell Reports demonstrating that NervGen’s proprietary drug, NVG-291-R, promotes nervous system repair and significant functional recovery in a mouse model of severe ischemic stroke , even when... Read More

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 150,000 incentive stock options to a director exercisable at a price of $1.99 per share for a period of five years and that vest equally every three months over a one-year period. All... Read More

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that it has closed its previously announced non-brokered private placement (the "Private Placement") of 10,150,000 units of the Company at a price of US$1.50 per unit (the "Unit Price"), for aggregate gross proceeds... Read More

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 180,000 incentive stock options to a director exercisable at a price of $2.08 per share for a period of five years with vesting that is either time or performance based. All options... Read More

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will host a 1-hour panel discussion on May 18 at the 2022 American Spinal Cord Injury Association (ASIA) annual meeting being held in New Orleans, Louisiana. The panel discussion, entitled "Translating Positive results... Read More

Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events reported in second dose cohort with NVG-291 Successful completion of the second cohort establishes a clear pathway to selecting a dose for upcoming Phase 1b/2 clinical trials NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a... Read More